Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (CSTL) delivers innovative diagnostic solutions that transform cancer care through genomic insights. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in precision oncology diagnostics.
Access authoritative information about CSTL’s latest developments, including new test validations, clinical study results, and strategic partnerships. Our curated collection features earnings reports, regulatory milestones, and research breakthroughs across key focus areas like melanoma diagnostics and pharmacogenomics.
Stay informed about critical updates including:
- FDA-cleared test announcements
- Peer-reviewed study publications
- Financial performance reports
- Collaborative oncology initiatives
- Expanded clinical utility data
Bookmark this page for streamlined access to Castle Biosciences’ verified news. Check regularly for updates that impact diagnostic practices and investment considerations in the genomic testing sector.
AltheaDx has appointed Derek Maetzold to its Board of Directors, enhancing its leadership with expertise in diagnostics and management. Maetzold, CEO of Castle Biosciences (CSTL), has significant experience in growing molecular diagnostics businesses. His addition aims to drive AltheaDx’s growth strategy, especially in the demand for pharmacogenomics testing for mental health, intensified by the pandemic. AltheaDx's flagship product, NeuroIDgenetix, is a Medicare-reimbursed test that enhances clinical decision-making for anxiety and depression treatments.
Castle Biosciences (Nasdaq: CSTL) announces a ribbon-cutting ceremony for its new headquarters in Friendswood, Texas, on May 25, 2021, from 3:00 p.m. to 6:00 p.m. Central time. The expansion reflects the company's commitment to improving patient care in dermatology, particularly for skin cancer. In 2020, the workforce grew by nearly 50%, with further hiring expected in 2021. The new facility will support the company's growth and development of genomic tests, including DecisionDx series for various skin cancers. Castle aims to enhance its offerings in dermatologic diagnostics.
Castle Biosciences (Nasdaq: CSTL) announced a collaboration with the American Skin Association to fund melanoma research. The ASA Castle Biosciences Research Grant was awarded to Dr. Joel Sunshine of Johns Hopkins for his study on 'mRNA Nanoparticle Vaccination for Melanoma Immunotherapy.' CEO Derek Maetzold emphasized the company's commitment to advancing dermatologic disease treatments. ASA has funded over $50 million in melanoma research, underscoring its long-standing dedication to skin disease advancements.
Castle Biosciences (Nasdaq: CSTL) announced a publication in the Journal of Drugs in Dermatology detailing the integration of its DecisionDx-SCC gene expression profiling test into clinical practice for squamous cell carcinoma (SCC). The study emphasizes that DecisionDx-SCC is a significant predictor of metastatic risk, surpassing traditional staging methods. Key points include its utility in nodal evaluation, adjuvant radiation therapy, and surveillance, potentially improving treatment decisions and reducing unnecessary procedures. The company aims to enhance personalized care for high-risk SCC patients.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced participation in the Oppenheimer MedTech, Tools, & Diagnostics Summit on May 26, 2021. CEO Derek Maetzold and CFO Frank Stokes will deliver a pre-recorded investor presentation and hold virtual one-on-one meetings. The presentation will be accessible on the conference site and Castle's website from May 26 to June 16, 2021. Castle specializes in personalized genomic information for dermatologic diagnostics, offering tests for various skin cancers and conditions.
Castle Biosciences (Nasdaq: CSTL) has appointed Tiffany Olson to its board of directors, effective immediately. Olson, who has extensive experience in public diagnostics, is expected to enhance the company’s strategic direction. Currently the president of Nuclear & Precision Health Solutions at Cardinal Health, Olson previously held leadership roles at NaviMed and Roche Diagnostics. She is recognized for her contributions to personalized medicine and has received several awards. Her appointment aims to strengthen Castle's board with her insights into high-growth operations.
Castle Biosciences (CSTL) reported a 31% revenue increase to $22.8 million for Q1 2021 compared to $17.4 million in Q1 2020. Notably, March 2021 saw a 30% rise in orders for the DecisionDx®-Melanoma test. The company anticipates 2021 revenues between $80-83 million. Gross margins were strong at 87%, with total gene expression profile test reports reaching 5,142. Castle also announced plans to acquire Myriad myPath Laboratory enhancing its service offerings. The expanded commercial team aims to improve patient care through innovative genomic tests.
Castle Biosciences, Inc. (Nasdaq: CSTL) has initiated a pipeline initiative to develop a genomic test predicting therapy responses for moderate to severe psoriasis and atopic dermatitis. This initiative expands their focus beyond cancer diagnostics. The company aims to launch the test by the end of 2025, potentially adding $1.9 billion to their U.S. total addressable market. A multi-center study involving 4,800 patients will support the test's development. This innovative approach could enhance patient care by optimizing early treatment decisions and reducing healthcare costs.
